AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

OGN · NYSE · Drug Manufacturers - General

Organon (OGN)

Commercializes women's health medicines, biosimilars, and established brands.

$13.71

vs last close+0.00 (+0.04%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	1,519	1,598	1,622	1,607	1,582	1,592	1,513	1,594	1,602	1,507	1,460	1,558
Cost of revenue	612	683	665	668	659	696	672	720	745	748	677	711
Gross profit	907	915	957	939	923	896	841	874	857	759	783	847
	675	603	543	553	533	600	516	548	499	524	517	524
Research & development	137	134	112	116	111	130	96	95	84	91	93	90
	538	469	431	437	422	470	420	453	415	433	424	434
Selling & marketing	0	0	0	0	0	206	0	0	0	0	0	0
General & administrative	0	0	0	0	0	264	0	0	0	0	0	0
Operating income	232	312	414	386	390	296	325	326	358	235	266	323
	−152	−208	−178	−151	−183	−167	−224	−97	−115	−383	−53	−140
Interest expense	134	129	131	131	126	132	124	132	128	121	111	108
Other non-operating income	18	79	47	20	57	31	100	−34	−13	262	−58	32
Income before tax	80	104	236	235	207	129	101	229	243	−148	213	183
Income tax expense	22	−442	35	40	−152	20	14	84	83	57	67	75
Net income from continuing operations	58	546	201	195	359	109	87	145	160	−205	146	108
Net income	58	546	201	195	359	109	87	145	160	−205	146	108
EPS, basic	$0.23	$2.14	$0.78	$0.76	$1.39	$0.42	$0.34	$0.56	$0.62	−$0.79	$0.55	$0.41
EPS, diluted	$0.23	$2.13	$0.78	$0.75	$1.38	$0.42	$0.33	$0.56	$0.61	−$0.79	$0.55	$0.40
Weighted average shares, basic	256	256	256	257	257	258	258	260	260	260	260	263
Weighted average shares, diluted	256	257	258	259	260	260	261	260	261	260	263	270
EBITDA	275	293	432	432	402	341	325	449	460	65	410	371
Depreciation & amortization	61	60	65	66	69	76	100	89	89	92	86	80
EBIT	214	233	367	366	333	265	225	360	371	−27	324	291